EP188: Lifting Pharma Credibility and Trustworthiness With Certified Medical Affairs Teams, With Dr. William Soliman
June 28, 2018
188
33:35

EP188: Lifting Pharma Credibility and Trustworthiness With Certified Medical Affairs Teams, With Dr. William Soliman

An experienced senior executive with several years of experience in the pharmaceutical and biotechnology industry, Will has held key positions where he was instrumental in launching a variety of innovative platforms in medical affairs. He speaks frequently regarding the ever-changing role of medical affairs at most major medical affairs conferences and is currently president and CEO of the ACMA, whose primary mission is to create industry standards and goals for medical affairs professionals.

Will Soliman has held key management roles across the industry within medical affairs, such as at Eisai, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim, and Merck. Will previously also served as vice president of medical and scientific affairs at CME LLC, a leading provider of continuing medical education to health care providers nationwide. He also has worked on the strategic management consulting side with companies such as Veeva Systems and often provides medical affairs consultancy services for Bain, McKinsey, BCG, Atheneum Partners, and Alpha Insights.

He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity, where he has collaborated with some of the nation’s top research institutions, such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania’s Center for Weight & Eating Disorders. Will was most recently invited to speak at the Center for Medical Technology Policy’s (CMTP) conference on Comparative Effectiveness Research to help inform payers, health care policy makers, physicians, and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among prediabetic overweight and obese individuals. In 2008, Will published a book entitled The Rise of Chemistry: Implications for Industry and Education.

He has also held several academic appointments at Seton Hall University’s School of Health and Medical Sciences; New Jersey City University; Kean University’s College of Natural, Applied, and Health Sciences; and Touro Colleges of Osteopathic Medicine, Pharmacy, and Physical Therapy teaching a variety of courses, including clinical therapeutics, pharmacology, pathophysiology, and epidemiology.

Will has served as a board member for the MSL Institute. He is a member of several organizations, including the American College of Cardiology (ACC), the American Diabetes Association (ADA), The Obesity Society (TOS), the American Association of Clinical Endocrinology (AACE), the American Society of Bariatric Physicians (ASBP), the American Heart Association (AHA), the Drug Information Association (DIA), and the American Chemical Society (ACS).


00:00 Will’s background and how he became president and CEO of the ACMA.
02:30 The difference between a sales rep and a medical science liaison (MSL).
04:35 The need for better education among medical affairs and pharma workers.
09:10 Working with key thought leaders and the Consensus Statement they are currently working on.
12:00 How accreditation courses work to help MSLs provide more of a balanced view of a pharma product.
15:50 The pressure for Pharma and manufacturers to become Outcomes Companies.
16:25 How are MSLs evolving?
17:20 “Really, what is the value of the product?”
22:00 How ACMA remains unbiased in their course curriculum.
23:15 How health care providers can verify that they are getting the clearest unbiased pharma information possible from their MSLs.
25:25 EP187 with Sandra Leal and Todd Eury, EP181 with Dr. Lipi Roy.
25:40 The state of opioid addiction in America and how pharma information contributed to the problem.
30:05 EP148 and AEE2 with Jennifer Miller.
30:25 “It’s time there’s a third party that’s vetting what we’re doing.”
32:40 You can learn more at medicalaffairsspecialist.org.

healthcare,pharma,acma,certified medical affairs,
|
|

Episode Support Provided By

Special Thanks to Our 2026 Sustaining Monthly Donors

Marilyn Bartlett, Kimberly Carleson, Dylan Yahn, Benjamin Light, Matt McQuideAnn Kempski, Spencer Allen, Scott Tromanhauser, 
Steven Elkins, Matthew Bunte, and Lori Smith.

Recent Episodes

EP519: The Current State of Primary Care—Inevitable or Fixable? With Lisa Rosenbaum, MD
Relentless Health ValueJuly 08, 2026
519
40:0036.61 MB

EP519: The Current State of Primary Care—Inevitable or Fixable? With Lisa Rosenbaum, MD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Today, let's start here. Right now, we are watching a very visible exodus of brilliant, consummate primary care (and other, honestly) physicians leaving traditional practice for concierge medicine or otherwise. For a full transcrip...

EP518: How Do You Explain the Difference Between an ASO Vendor and a TPA? With Claire Brockbank
Relentless Health ValueJuly 01, 2026
518
14:2513.2 MB

EP518: How Do You Explain the Difference Between an ASO Vendor and a TPA? With Claire Brockbank

Listen on Your Favorite App Dr. Alex Sommers: Hi. I'm Alex Sommers. I'm president of Astia Health, an advanced direct primary care organization, an emergency medicine and lifestyle medicine physician, as well as a licensed employer health plan advisor from Wisconsin. I'm curious how you explain the ...

EP517: The Business of Prior Auths: The 401-Level Financial Motive Behind Prior Auths
Relentless Health ValueJune 24, 2026
517
27:2325.07 MB

EP517: The Business of Prior Auths: The 401-Level Financial Motive Behind Prior Auths

Listen on Your Favorite App Hello, Relentless Health Value Tribe. Welcome to it. So, yeah … last week, I had a great conversation with Ophelia Johnson ( EP516 ) that is a companion show, I would say, to this one. So, listen to that one first. Listen to this one first. You do you. For a full transcri...

EP516: GLP-1s and Cash Pay From the Pharma Manufacturer Point of View, With Ophelia Johnson
Relentless Health ValueJune 17, 202644:0540.35 MB

EP516: GLP-1s and Cash Pay From the Pharma Manufacturer Point of View, With Ophelia Johnson

Listen on Your Favorite App Hello, all you Relentless Tribe members. Welcome to it. Today we have a show that will bend your mind in new directions. And yes, I have a head cold at a very weird time of year. I have trouble apparently doing things like normal people. Anyway, we talk a lot on this podc...

EP515: SNF (Skilled Nursing Facility) Fraud—Or Is It Fraud? With Michelle Cera, PhD
Relentless Health ValueJune 10, 202643:0739.47 MB

EP515: SNF (Skilled Nursing Facility) Fraud—Or Is It Fraud? With Michelle Cera, PhD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Lately, I have been just obsessed with what's hiding in plain sight: the root cause glitches in how American healthcare is built. Not the symptoms now. Not the noise. The actual ground zero. I mean, what we call healthcare in this ...

EP514: Successfully Suing a Health System for Their Anticompetitive Contracts and Also Collecting Damages for Plan Sponsors and Members, With Matt Cantor
Relentless Health ValueJune 03, 2026
514
43:4340.02 MB

EP514: Successfully Suing a Health System for Their Anticompetitive Contracts and Also Collecting Damages for Plan Sponsors and Members, With Matt Cantor

Listen on Your Favorite App Hello, all you Relentless Tribe members. This is the third episode in our legal goings-on trifecta, starting with Doug Aldeen in episode 512 covering what amounts to the main reasons plan sponsors wind up suing their brokers or employee benefit consultants. For a full tra...

EP513: Revisiting Cunning Anticompetitive Hospital Contracts, With Brennan Bilberry

EP513: Revisiting Cunning Anticompetitive Hospital Contracts, With Brennan Bilberry

Listen on Your Favorite App If you are a large employer, union funds broker, fiduciary, or anyone responsible for a health plan that spends half of its dollars on hospital care (which most do), or if you have anything to do with policy or enforcement of policy, yeah … listen this week and next week....

Listen and Follow

Sponsored by Aventria Health Group
©2026 BD Bridges LLC. All Rights Reserved.